Agilisium announced an INR 50 Crore investment — close to USD 5.5 million — to transform how pharmaceutical, biotech and medtech enterprises operationalise Artificial Intelligence (AI). At the heart of this initiative is the development and deployment of Forward Deployment Experts (FDX), a new professional standard defined by Agilisium built across four dimensions: Domain, AI and Technology, Consultative Solutioning and Systems and Process Thinking.

Unlike traditional AI services, FDX professionals are embedded directly inside life sciences organisations working alongside scientific, regulatory and commercial teams not advising from the outside, but driving transformation from within. The investment will reskill and deploy Agilisium's global workforce of more than 1,000 professionals as embedded AI transformation partners, making this the world's first forward deployment experts built exclusively for life sciences.

Raj Babu, Founder and CEO, Agilisium, said, “The biggest constraint in AI adoption in life sciences is no longer technology; it is talent. The companies that will lead life sciences in the next decade will not be the ones that simply purchase AI models. They will be the ones that embed AI capability deep inside their organisations. At Agilisium, our advantage comes from the compounding institutional and domain knowledge we have built by focusing exclusively on life sciences.”

“Our FDX team is crucial to staying ahead of the curve and delivering innovative solutions for our clients. By integrating AI, innovation and execution, we are building an operating model that translates intelligence into real-world impact at scale,” said  Arunkumar Arjunan, Chief Operating Officer and Chief AI and Innovation Officer, Agilisium.

Agilisium’s forward-deployment model combines deep life sciences domain expertise with AI engineering and data science capability and then keeps both inside the client’s organisation for the duration of the transformation. Agilisium professionals sit beside scientists, clinical teams, regulatory leaders and commercial stakeholders, designing, deploying and continuously operating AI-driven capabilities rather than handing them over.

“Building the FDX standard is about creating real value for our clients by combining AI literacy, deep domain understanding and a strong focus on measurable outcomes. This is not an upskilling talent, but a fundamental transformation,” said Hemapriya Dharshini, Senior Vice President, Agilisium.

This approach is designed to move life sciences enterprises beyond the pilot trap, the persistent cycle of proof-of-concepts that demonstrate value, but never reach production scale. The forward-deployment model stakes Agilisium’s commercial success on whether the AI works inside the client’s environment, not on whether the engagement was delivered.

“Building capabilities at the intersection of domain, technology and AI-driven systems are fundamental to scaling AI in life sciences. The FDX standard is designed to develop professionals who can seamlessly bridge these areas and drive sustained transformation across the value chain,” said Venkatesa Prasad Neelamegam, Chief Capabilities Officer, Agilisium.

To operationalise the forward deployment model, the company introduced three integrated service offerings anchored by FDX:

Forward Deployment Experts (FDX): Senior practitioners who sit inside a client’s organisation are not offsite in a consulting office and rebuild scientific, regulatory and commercial workflows with AI at their core. FDX is a new professional standard defined by expertise across four intersecting dimensions: Domain, AI & Technology, Consultative Solutioning, and Systems & Process Thinking. These are not project managers or advisors; they are multi-dimensional experts who own outcomes.

Forward-Deployment Agents (FDA): Autonomous AI agents trained each enterprise’s proprietary data, regulatory frameworks and operational logic, not generic foundation models adapted from the outside. These agents are context-centric by design, built to operate within the specific compliance and scientific environment of each client.

Forward-Deployment Services (FDS): Managed teams that remain embedded after initial deployment continuously running, optimising and evolving AI capabilities through every model lifecycle. Customers do not inherit technical debt when the engagement closes; they inherit a functioning, improving system.

Together, FDX, FDA and FDS are designed to close the gap between AI experimentation and AI at scale across the full drug development and commercialisation lifecycle.

Across the industry, organisations face a growing shortage of professionals who combine deep domain expertise with AI engineering capability and regulatory awareness. The problem is not a shortage of AI engineers, nor a shortage of life scientists; it is a shortage of professionals who are both, and who understand how to operate within the highly regulated, data-sensitive environment that life sciences demands. Agilisium’s FDX standard is purpose-built to fill this gap.

Agilisium’s INR 50 crore workforce transformation initiative will fund structured training, domain capability development and immersive client engagement models designed to develop and certify professionals to the FDX standard.